StockNews.AI

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

StockNews.AI • 3 hours

PTLAKORSAMBI
High Materiality10/10

Information

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suf...

Original source

AI Summary

Shares of AQST fell 40% after FDA NDA deficiencies. FDA concerns about Anaphylm's approvability ahead of January deadline. Investigation launched into potential investor claims against AQST.

Sentiment Rationale

The 40% drop indicates a severe market reaction to regulatory setbacks, akin to historical FDA failures leading to significant stock declines in biotechs.

Trading Thesis

Immediate investor reaction to FDA issues will likely continue through PDUFA date and Q1 2026.

Market-Moving

  • Shares of AQST fell 40% after FDA NDA deficiencies.
  • FDA concerns about Anaphylm's approvability ahead of January deadline.
  • Investigation launched into potential investor claims against AQST.

Key Facts

  • Shares of AQST fell 40% after FDA NDA deficiencies.
  • FDA concerns about Anaphylm's approvability ahead of January deadline.
  • Investigation launched into potential investor claims against AQST.

Companies Mentioned

  • PTLA (PTLA)
  • KORS (KORS)
  • AMBI (AMBI)

Legal

The regulatory setback drastically affects AQST's future prospects, warranting high investor concerns.

Investor Alert: Faruqi & Faruqi, LLP Investigates Claims for Investors of Aquestive Therapeutics (AQST)

NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently investigating potential claims on behalf of investors who have suffered significant losses in Aquestive Therapeutics, Inc. (NASDAQ: AQST). This investigation arises in light of recent developments concerning the company, focusing on their New Drug Application (NDA) for Anaphylm, a treatment for severe allergic reactions.

Recent Stock Performance of AQST

Shares of Aquestive Therapeutics experienced a substantial decline, plummeting approximately 40% intraday on Friday. This drastic drop occurred after the U.S. Food and Drug Administration (FDA) disclosed that they identified deficiencies in the NDA for Anaphylm. The deficiencies cited by the FDA hindered discussions regarding labeling and post-marketing requirements, raising significant concerns about the approvability of the application before the critical January 31, 2026, PDUFA action date.

Legal Rights for Investors

Faruqi & Faruqi is extending its services to investors affected by the recent downturn in AQST's stock value. Investors who have experienced financial losses are encouraged to reach out to Josh Wilson, a partner at the firm, to explore their legal options. Interested parties can contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

  • Significant decline in Aquestive Therapeutics stock.
  • Investigation launched by Faruqi & Faruqi for potential claims.
  • FDA identified deficiencies in the NDA for Anaphylm.
  • Concern over the January 31, 2026, PDUFA action date.

About Faruqi & Faruqi, LLP

Founded in 1995, Faruqi & Faruqi has established itself as a leading force in the national securities law arena, recovering hundreds of millions for investors across various cases. With offices in New York, Pennsylvania, California, and Georgia, the firm is positioned to handle a broad spectrum of securities litigation issues.

Next Steps for Investors

Investors are urged to stay informed about the ongoing investigation into Aquestive Therapeutics and to consider their legal options if they experienced losses. More information is available at www.faruqilaw.com/AQST.

For continuous updates, follow Faruqi & Faruqi on LinkedIn, on X, or on Facebook.

Attorney Advertising: The law firm responsible for this advertisement is Faruqi & Faruqi, LLP. Previous results do not guarantee or predict a similar outcome in any future matter. All communications will be treated confidentially.

Related News